FACULTY SCHOLARSHIP
Presentations
Allen I. White Distinguished Associate Professor of Pharmacotherapy Joshua Neumiller and co-presenters lead a virtual town hall titled, “Focus on the evolving role of GLP-1 receptor agonists,” for Postgraduate Healthcare Education on October 15, 2020. The topic examined the role of GLP-1 receptor agonists in the management of Type 2 diabetes is continually evolving, challenging pharmacists to stay current with the latest science.
Service
Josh Neumiller served on the Steering Committee for the IDEA 2.0: Innovating Decisions and Empowering Action in Diabetes Management program on use of continuous glucose monitors (CGM) sponsored by the American Association of Clinical Endocrinology (AACE).
See the free educational initiative
Pharmaceutical Sciences Professor Mary Paine served as guest editor to the, “Natural products: experimental approaches to elucidate disposition mechanisms and predict pharmacokinetic drug interactions,” section of the October 2020 issue of Drug Metabolism and Disposition.
Josh Neumiller served as a faculty member for the ASHP Diabetes Management Certificate program.
Grants/Awards
Pharmaceutical Sciences Assistant Professor John Clarke received an R56 award from the National Institutes of Health in the amount of $222,910 over one year for the project, “Risk of xenobiotic-drug interactions in chronic disease.”
STUDENT ACHIEVEMENT
Doctor of Pharmacy (PharmD) students
Sabrina Judson, class of 2022, created the cover art for the October issue of Drug Metabolism and Disposition. The issue also contains a special section, “Natural Products: Experimental Approaches to Elucidate Disposition Mechanisms and Predict Pharmacokinetic Drug Interactions,” of which Pharmaceutical Sciences Professor Mary Paine was the guest editor. Sabrina also a student in Mary Paine’s lab.
Lynn Luu, class of 2020, with faculty co-author Joshua Neumiller published the case study “Using newer glucagon product,” on Diabetes in Control in October 2020.
Kylee Shriver, class of 2020, published “Bempedoic acid: a novel LDL cholesterol–lowering agent,” Clinical Diabetes in October 2020.